Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013–2018

Table 4 Time series coefficients for linear trend estimates and 95% confidence intervals of genetic testing trends by age and sex

	Male			Female
	<18 Years n=448,145 β* (95% CI)	18-64 Years n=999,776 β^a (95% CI)	> 65 Years n=251,642 β^a (95% CI)	<18 Years n=413,708 β^a (95% CI)	18-64 Years n=1,207,273 β^a (95% CI)	> 65 Years n=372,618 β^a (95% CI)
HBOC testing	-	0.20 (0.11, 0.29) P-value: <0.001	0.16 (-0.02, 0.34) P-value: 0.074	-	1.12 (0.43, 1.82) P-value: 0.004	0.22 (-0.34, 0.78) P-value: 0.411
Lynch syndrome testing	-	0.16 (0.02, 0.31) P-value: 0.033	0.19 (-0.01, 0.39) P-value: 0.064	-	0.19 (-0.01, 0.38) P-value: 0.062	0.16 (0.07, 0.25) P-value: 0.003
Tier 2 molecular pathology procedures^b	0.11 (-0.31, 0.54) P-value: 0.575	-0.91 (-2.69, -0.87) P-value: 0.289	6.68 (0.38, 12.98) ivalue: 0.039	0.13 (-0.16, 0.41) P-value: 0.350	-0.49 (-3.06, 2.08) P-value: 0.687	0.72 (-5.62, 7.06) P-value: 0.810
Any cancer genetic testing^c	0.11 (-0.34, 0.57) P-value: 0.606	-0.06 (-1.86, 1.74) P-value: 0.946	7.35 (1.22, 13.47) P-value: 0.022	0.16 (-0.11, 0.42) P-value: 0.229	1.18 (-1.70, 4.07) P-value: 0.392	1.41 (-4.93, 7.76) P-value: 0.737

HBOC Hereditary Breast and Ovarian Cancer
^a β represents the linear change per 100,000 persons per quarter
^b Tier 2 molecular pathology procedures are based on the complexity of the testing technique and are not specific to a gene or hereditary cancer syndrome
^c Any cancer genetic testing included tests in the HBOC, Lynch syndrome, Tier 2 molecular pathology procedures, and other hereditary cancer syndrome (HCS) panel categories

ISSN: 1897-4287